Latest & greatest articles for lamotrigine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lamotrigine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lamotrigine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lamotrigine

21. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Full Text available with Trip Pro

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Carbamazepine is widely accepted as a drug of first choice for patients with partial onset seizures. Several newer drugs possess efficacy against these seizure types but previous randomised controlled trials have failed to inform a choice between these drugs. We aimed to assess efficacy with regards to longer-term (...) outcomes, quality of life, and health economic outcomes.SANAD was an unblinded randomised controlled trial in hospital-based outpatient clinics in the UK. Arm A recruited 1721 patients for whom carbamazepine was deemed to be standard treatment, and they were randomly assigned to receive carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate. Primary outcomes were time to treatment failure, and time to 12-months remission, and assessment was by both intention to treat and per protocol

2007 Lancet Controlled trial quality: predicted high

22. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Full Text available with Trip Pro

The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Valproate is widely accepted as a drug of first choice for patients with generalised onset seizures, and its broad spectrum of efficacy means it is recommended for patients with seizures that are difficult to classify. Lamotrigine and topiramate are also thought to possess broad spectrum activity. The SANAD study aimed to compare (...) the longer-term effects of these drugs in patients with generalised onset seizures or seizures that are difficult to classify.SANAD was an unblinded randomised controlled trial in hospital-based outpatient clinics in the UK. Arm B of the study recruited 716 patients for whom valproate was considered to be standard treatment. Patients were randomly assigned to valproate, lamotrigine, or topiramate between Jan 12, 1999, and Aug 31, 2004, and follow-up data were obtained up to Jan 13, 2006. Primary outcomes

2007 Lancet Controlled trial quality: predicted high

23. The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder

The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder Calvert N W, Burch S P, Fu A Z, Reeves P, Thompson T R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined several maintenance treatments for adults with bipolar I disorder (BD-I). These were lamotrigine (LAM), lithium (LIT) and olanzapine (OLA). LAM was given at 200 mg/day, LIT at 900 mg/day and OLA at 12.5 mg/day. All treatments were given during the euthymic phase of BD-I for the prevention of episodes

2006 NHS Economic Evaluation Database.

24. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. (Abstract)

Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Absence seizures are brief epileptic seizures which present in childhood and adolescence. They are characterised by sudden loss of awareness and an electroencephalogram (EEG) typically shows generalised spike wave discharges at three cycles per second. Ethosuximide, valproate and lamotrigine are currently used to treat absence seizures. This review aims to determine the best choice of anticonvulsant (...) for a child with typical absence seizures.To review the evidence for the effects of ethosuximide, valproate and lamotrigine as treatments for children and adolescents with absence seizures, when compared with placebo or each other.We searched the Cochrane Epilepsy Group's Specialised Register (March 2005), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2005), MEDLINE (1966 to March 2005) and EMBASE (1988 to March 2005). No language restrictions were imposed

2005 Cochrane

25. Lamotrigine and lithium are effective maintenance treatments in recently depressed people with bipolar I disorder Full Text available with Trip Pro

Lamotrigine and lithium are effective maintenance treatments in recently depressed people with bipolar I disorder Lamotrigine and lithium are effective maintenance treatments in recently depressed people with bipolar I disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Lamotrigine and lithium are effective maintenance treatments in recently depressed people with bipolar I disorder Article Text Therapeutics Lamotrigine and lithium

2005 Evidence-Based Mental Health

26. Cost-effectiveness of add-on lamotrigine therapy in clinical practice

Cost-effectiveness of add-on lamotrigine therapy in clinical practice Cost-effectiveness of add-on lamotrigine therapy in clinical practice Cost-effectiveness of add-on lamotrigine therapy in clinical practice Knoester P D, Boendermaker A J, Egberts A C, Hekster Y A, Keyser A, Severens J L, Renier W O, Deckers C L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Patients with epilepsy that were either not controlled or were suffering from intolerable side effects from medication were given lamotrigine (LTG) as an add-on therapy. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The patients were at least 18 years old. All patients were receiving add-on LTG therapy

2005 NHS Economic Evaluation Database.

27. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. (Abstract)

Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Absence seizures are brief epileptic seizures which present in childhood and adolescence. They are characterised by sudden loss of awareness and an electroencephalogram (EEG) typically shows generalised spike wave discharges at three cycles per second. Ethosuximide, valproate and lamotrigine are currently used to treat absence seizures. This review aims to determine the best choice of anticonvulsant (...) for a child with typical absence seizures.To review the evidence for the effects of ethosuximide, valproate and lamotrigine as treatments for children and adolescents with absence seizures, when compared with placebo or each other.We searched the Cochrane Epilepsy Group trials register, the Cochrane Central Register of Controlled Trials (The Cochrane Library issue 1, 2003), MEDLINE (January 1966 to March 2003) and EMBASE (1988 to March 2003). We also contacted Sanofi Winthrop, Glaxo Wellcome (now

2003 Cochrane

28. Lamotrigine add-on for drug-resistant partial epilepsy. (Abstract)

Lamotrigine add-on for drug-resistant partial epilepsy. Epilepsy is a common neurological disorder, affecting almost 0.5 to 1% of the population. Nearly 30% of patients with epilepsy are refractory to currently available drugs. Lamotrigine is one of the newer antiepileptic drugs and is the topic of this review.To examine the effects of lamotrigine on seizures, side effects, cognition and quality of life, when used as an add-on treatment for patients with drug-resistant partial epilepsy.We (...) searched the Cochrane Epilepsy Group trials register, the Cochrane Controlled Trials Register (Cochrane Library Issue 1, 2000), MEDLINE (January 1966 to December 1999) and reference lists of articles. We also contacted the manufacturers of lamotrigine (Glaxo-Wellcome).Randomized placebo controlled trials, of patients with drug-resistant partial epilepsy of any age, in which an adequate method of concealment of randomization was used. The studies may be double, single or unblinded. For crossover studies

2000 Cochrane

29. Economic analysis of epilepsy treatment: a cost minimization analysis comparing carbamazepine and lamotrigine in the UK

Economic analysis of epilepsy treatment: a cost minimization analysis comparing carbamazepine and lamotrigine in the UK Economic analysis of epilepsy treatment: a cost minimization analysis comparing carbamazepine and lamotrigine in the UK Economic analysis of epilepsy treatment: a cost minimization analysis comparing carbamazepine and lamotrigine in the UK Shakespeare A, Simeon G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) Further prospective studies are required to confirm the conclusions of clinical analysis and to generate more information on the use of resources. Source of funding None stated. Bibliographic details Shakespeare A, Simeon G. Economic analysis of epilepsy treatment: a cost minimization analysis comparing carbamazepine and lamotrigine in the UK. Seizure 1998; 7(2): 119-125 PubMedID Other publications of related interest Brodie M J, Richens A and Yuen A W C. Double blind comparison of lamotrigine

1998 NHS Economic Evaluation Database.

30. An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy

An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy Heaney D C, Shorvon S D, Sander J W Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Four drugs used in monotherapy during the first two years of treatment for newly diagnosed patients with epilepsy were compared. These were Carbamazepine (CBZ), Phenytoin (PHT), Valproate (VPA) and Lamotrigine (LTG). Type

1998 NHS Economic Evaluation Database.

31. Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy

Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy Markowitz M A, Mauskopf J A, Halpern M T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) from literature published between 1992 and 1998. The price years used were not stated. Source of effectiveness data Effectiveness data were derived from a review or synthesis of previously published studies Modelling A decision analysis model was used to combine information on clinical effectiveness and cost/resource use data identified from published literature. The model considered the impact of adjunctive lamotrigine therapy on costs and health outcomes for patients over a 10 year period

1998 NHS Economic Evaluation Database.

32. Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis

Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis Messori A, Trippoli S, Becagli P, Cincotta M, Labbate M G, Zaccara G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Using adjunctive lamotrigine (either 300mg or 500mg per day) therapy as add-on treatment to currently available antiepileptic drugs (AEDs) versus no adjunctive therapy (placebo-controlled, only AEDs) in the treatment of patients with refractory partial seizures. Type of intervention Treatment. Economic study

1998 NHS Economic Evaluation Database.

33. Lamotrigine as monotherapy for epilepsy in adults

Lamotrigine as monotherapy for epilepsy in adults Lamotrigine as monotherapy for epilepsy in adults Lamotrigine as monotherapy for epilepsy in adults Bryant J, Stein K Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bryant J, Stein K. Lamotrigine as monotherapy for epilepsy in adults. Southampton: Wessex Institute for Health Research (...) and Development (WIHRD) 1998 Authors' objectives The author investigates whether lamotrigine should be used as monotherapy for treating epilepsy in adults, in place of the established antiepileptic drugs, and whether it should be used as add-on therapy. Authors' conclusions LTG may be a good option for patients with poorly controlled epilepsy due to treatment-limiting side effects, and those with a history of drug intolerance but adequate seizure control, but skin reactions are common and may be serious

1998 Health Technology Assessment (HTA) Database.

34. A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy

A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy A cost minimization study comparing vigabatrin, lamotrigine and gabapentin for the treatment of intractable partial epilepsy Hughes D, Cockerell O C Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) . Results of the review In the absence of head to head trials, there was no evidence that the efficacy of the three drugs differed significantly. On this basis, the authors decided to conduct a cost minimization study. The side effects of the three drugs are reported in terms of incidence, the aim being to estimate the resulting level of health service utilisation. For example, 9-15% of patients on lamotrigine, 6-15% of patients on vigabatrin and 3-7% of patients on gabapentin suffer from major side

1996 NHS Economic Evaluation Database.

35. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. (Abstract)

Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lamotrigine has been licensed widely as adjunctive therapy for partial and secondary generalised seizures. Use of the drug as monotherapy was investigated in a double-blind, randomised, parallel-group comparison with carbamazepine in newly diagnosed epilepsy. After 4 weeks of planned, fixed dose escalation, doses were adjusted according to efficacy, adverse (...) events, and plasma concentrations. 151 of 260 patients (131 lamotrigine, 129 carbamazepine) in eight UK centres completed the 48-week trial. No differences in efficacy between the drugs were found for partial seizures with or without secondary generalisation or for primary generalised tonic-clonic seizures. The proportion of patients maintained seizure-free during the last 24 weeks of treatment was almost the same in both groups (39% lamotrigine, 38% carbamazepine). More patients with primary

1995 Lancet Controlled trial quality: predicted high